Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Scott_Wolchko
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:CUSIP |
31189P102
|
| gptkbp:focus |
gptkb:cancer
immune disorders cellular immunotherapies |
| gptkbp:foundedYear |
2007
|
| gptkbp:hasCompany |
Fate Therapeutics, Inc.
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ:FATE
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US31189P1021
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:market |
gptkb:NASDAQ_Global_Market
|
| gptkbp:stockSymbol |
gptkb:NASDAQ
gptkb:FATE |
| gptkbp:website |
https://fatetherapeutics.com
|
| gptkbp:bfsParent |
gptkb:Fate_Therapeutics
|
| gptkbp:bfsLayer |
7
|